The Trump administration is moving to speed up approvals of copycat biologic drugs as a way to lower health costs and boost ...

AbbVie recently reported record 2025 results and outlined a stronger 2026 outlook, while advancing key immunology assets and completing the VOLITE skin quality aesthetics trial to bolster its ...

Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences those businesses and shapes what we all pay for care. He is also ...

President Donald Trump's trade and manufacturing adviser Peter Navarro said on Sunday that the White House may force data center builders to absorb utility costs. Data centers powering artificial ...

This is read by an automated voice. Please report any issues or inconsistencies here. As outrage spreads over energy-hungry data centers, politicians from President Trump to local lawmakers have found ...

Americans have long lamented the high cost of health insurance, and the situation will soon get worse. Premiums for employer-sponsored insurance will go up by another 9 percent in 2026. Public ...

For as long as I can remember, even before “affordability” became a prominent theme in American public discourse, politicians and pundits have tracked the prices of homes, gasoline, milk, eggs, and ...

It’s cold outside — and a fine time to look over your bills and see where you can save. By Ann Carrns My bill for internet service had gone up, and I didn’t know why. I wasn’t getting faster speeds, ...

MedImpact Holdings, Inc. today announced the launch of an unbranded biosimilar to Humira(R) (adalimumab) priced at 95% below the brand-name cost. MedImpact is offering this biosimilar (adalimumab-ryvk ...

The product is priced at 95% below the brand-name cost. Ease of adoption. The product is FDA-designated as interchangeable and supported by innovative prescriber and patient engagement programs to ...

MedImpact Holdings, Inc. today announced the launch of an unbranded biosimilar to Humira® (adalimumab) priced at 95% below the brand-name cost. MedImpact is offering this biosimilar (adalimumab-ryvk), ...